Journal of vascular and interventional radiology : JVIR · 2026
Mechanical Thrombectomy for High-Risk Pulmonary Embolism on Extracorporeal Membrane Oxygenation: A Single-Center Retrospective Case Series.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gorodezky Andrea, Barral Ernest, Medema Alexis, Kim Charles, Mastria Eric M, Ronald James, Solomon Alex J, Triana Brian, Wong An-Kwok Ian, Martin Jonathan G
Аннотация
PURPOSE: To evaluate the use of mechanical thrombectomy (MT) in patients who require venoarterial extracorporeal membrane oxygenation (VA-ECMO) for the management of acute high-risk pulmonary embolism.
MATERIALS AND METHODS: This retrospective case series included patients who underwent VA-ECMO followed by MT for the treatment of pulmonary embolism between January 2017 and December 2025. Clinical, laboratory, and imaging data were collected from the electronic medical record. Outcomes included 30-day mortality and procedural adverse events. Potential risk factors for mortality were evaluated. Exploratory analyses between survivors and nonsurvivors were performed using the Mann-Whitney U test for continuous variables and Fisher exact test for categorical variables.
RESULTS: A total of 20 patients met inclusion criteria. The mortality rate was 15% (n = 3) at 48 hours, 35% (n = 7) at 30 days, and 45% (n = 9) at 6 months. Procedure-related adverse events were present in 45% (n = 9) of patients. Acute bleeding events occurred in 30% (n = 6) of patients, and neurologic events occurred in 15% (n = 3) of patients following ECMO cannulation and MT. No variables evaluated were significantly associated with mortality.
CONCLUSIONS: In this single-center retrospective cohort, patients undergoing MT while supported with VA-ECMO for high-risk pulmonary embolism demonstrated a 30-day mortality of 35%. Further studies including matched controls and larger cohorts are needed to better define the role of MT in this critically ill population.
MATERIALS AND METHODS: This retrospective case series included patients who underwent VA-ECMO followed by MT for the treatment of pulmonary embolism between January 2017 and December 2025. Clinical, laboratory, and imaging data were collected from the electronic medical record. Outcomes included 30-day mortality and procedural adverse events. Potential risk factors for mortality were evaluated. Exploratory analyses between survivors and nonsurvivors were performed using the Mann-Whitney U test for continuous variables and Fisher exact test for categorical variables.
RESULTS: A total of 20 patients met inclusion criteria. The mortality rate was 15% (n = 3) at 48 hours, 35% (n = 7) at 30 days, and 45% (n = 9) at 6 months. Procedure-related adverse events were present in 45% (n = 9) of patients. Acute bleeding events occurred in 30% (n = 6) of patients, and neurologic events occurred in 15% (n = 3) of patients following ECMO cannulation and MT. No variables evaluated were significantly associated with mortality.
CONCLUSIONS: In this single-center retrospective cohort, patients undergoing MT while supported with VA-ECMO for high-risk pulmonary embolism demonstrated a 30-day mortality of 35%. Further studies including matched controls and larger cohorts are needed to better define the role of MT in this critically ill population.